SOURCE: Alltracel Pharmaceuticals Plc

September 11, 2007 02:02 ET

Alltracel announces interim results for the six months ended June 30th, 2007

DUBLIN, IRELAND--(Marketwire - September 11, 2007) -

Alltracel Pharmaceuticals plc

    - Alltracel announces interim results for the six months ended 
                     June 30th, 2007 -
          - Significant improvement in profitability, EBITDA 
                   up to EUR592k versus EUR360k in H1 2006 -
          - Gross margin increased to 40% versus 36% in H1 06 -
  - Continued strong oral care trading and acquisition of Synpart AG
                       (post the period end)-
    - Technology development progress in Cardiovascular Health and
                   Nanotechnology sectors -

September 11, 2007: London, UK & Dublin, Ireland

Alltracel Pharmaceuticals Plc., ("Alltracel "), (AIM:AP.L), the Healthcare
Innovation Group focused on the Oral Care, Wound Care, Cardiovascular
Health and Dermal Health markets, today announces interim financial
results for the six months ended June 30th, 2007.

2007 First Half (H1 2007) Financial Highlights: Last years profitability 
growth continues into the first half of 2007.

*        Operating profit of EUR387k versus EUR71k in H1 2006
*        EBITDA of EUR592k versus EUR360k in H1 2006
*        Gross margin increased to 40% versus 36% in H1 2006
*        Revenue of EUR10.1M versus EUR9.5M in H1 2006
*        Closing cash balance of EUR2.3M
Summary Commentary

Commenting on the company's half year performance and recent developments, Chief Executive Officer, Tony Richardson said:

"The first half of 2007 has seen significant developments in trading profitability, scientific and commercial breakthroughs and significant M&A activity.

The profitability momentum achieved throughout last year has continued into this half year with all measures of profitability improving versus last year. This is attributable to generating higher margin sales revenues from the licensing and exploitation of technological know how through partnership arrangements.

Post the period end we announced on 31st August 2007 the acquisition of Synpart AG. We plan to integrate this acquisition with our existing specialist oral care division Westone and our consumer wound care business of m.docTM to form Synpart Limited, a specialist consumer products division. Once established, Synpart Limited will be the leading Sourcing & Development Partner for private label and proprietary brands in the European specialist oral care and wound care markets and will have a particular focus on technological innovation serviced by the recently established division, Alltracel Healthcare Services.

Our nanotechnology subsidiary Nanopeutics s.r.o continues to make encouraging scientific and commercial progress with previously announced breakthroughs in the professional and military markets. The concept development nanotechnology partnership with a global leader in professional wound care has now been officially extended following the successful conclusion of the first agreed stage. The revenue license deal with HemCon Medical Technologies, Inc., the haemorrhage control market leaders in military markets, is also progressing well and we remain on schedule for the market introduction of the resultant Chitosan-NanospiderTM technology in 2008. We will update the market on these two significant collaborations as appropriate.

Also partnership discussions are advancing with market leading potential partners in the consumer and industrial woundcare sectors incorporating nano-m.docTM.

Following formulation breakthrough on our patented bioactive technology for the Cardiovascular Health sector and subsequent development of a number of exciting novel delivery formats, we have formally extended partnership discussions to a number of new large scale potential partners. These partners now include Irish based global leaders in the functional ingredients and finished food markets. We remain on schedule and will update the market by year end.

PhytopeuticsTM - Dermal Health Solutions for Cosmeceuticals - is progressing in its six month co-funded product development programme and we expect to make further announcements on this in the fourth quarter.

Our priority for the remainder of the year will be to integrate the recent acquisition and focus on driving increased profitable revenue growth across the Group. However we will also consider additional appropriate earnings enhancing bolt-on acquisitions within our core specialties.

We remain confident in the outlook for the full year, and believe the new enlarged company is well positioned within each of the sectors that we operate."

Cautionary Statement Regarding Forward-Looking Statements

This announcement contains forward-looking statements. We have based these forward-looking statements on our current plans, expectations and projections about future events. Words like; "intend", "expect", "seek", "will", "plan", "could", "may", and similar expressions often identify forward-looking statements but are not the only ways of doing so. Forward-looking statements involve inherent risks and uncertainties arising from factors outside of our control, such as; financial conditions, regulatory developments, technological developments, activities of our competitors and other factors. We caution you that such factors may cause actual results to materially differ from those contained in forward-looking statements. The forward-looking statements are made only as of the date of this announcement and we do not intend, except as required by law, to update any forward-looking statements to reflect new information or subsequent events or circumstances.

To view the full text of this press release, paste the following link into your web browser:

                      This information is provided by RNS
            The company news service from the London Stock Exchange